ClinicalTrials.gg
CompletedNCT04846491Updated Mar 5, 2024

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

A Phase 3 interventional study of Peginterferon alfa-2b injection and Peginterferon alfa-2b injection in Chronic Hepatitis B, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Completed at 33 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2019, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic — 5 open to participants now, 5 under way, none of them phase 3. peginterferon alfa-2b · Hepatitis B, Chronic.

Enrollment
3rd of 15
475 · median 254
Started
2019
the only one that year
Phase 3
5 of 15
none open now
Registered
9th of 15
by date

Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 5 in phase 3, and was the 9th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • peginterferon alfa-2b injection
  • interferon alfa
  • nucleos(t)ide
  • NUCs
  • NAs
  • chronic hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand and sign the form voluntarily.
  • Age between 18 and 65 years (including 18 and 65), no gender limit.
  • -positive for at least 6 months or other evidence supporting chronic infection with hepatitis B virus.
  • HBsAg positive at screening.
  • For NAs treated patients: Who should have continuously taken NAs for at least 9 months prior to screening, and are currently receiving the NAs. Simultaneously, the patients should have achieved the following criteria: HBsAg\<1500IU/mL, HBV DNA\<100IU/ml, HBeAg\<10s/co at screening.
  • For treatment naive patients: HBV DNA≥1×10\^4IU/ml, and 2× (upper limit of normal) ≤≤10×ULN at screening.
  • Pregnancy test of female of childbearing must be negative within 24 hours before the first medication, and the subjects (male and female) should take effective measures during the whole study period.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, breastfeeding or planning to pregnant during the study period.
  • Subjects with neuropsychiatric diseases and/or neuropsychiatric family history, especially depression, anxiety, or mania schizophrenia.
  • Co-infected with Hepatitis A, , Hepatitis D, Hepatitis E, or .
  • Chronic hepatitis other than , e.g. alcoholic hepatitis, drugs-induced hepatitis, or hepatitis, etc.
  • Moderate to severe steatohepatitis.
  • Evidence of acute severe hepatitis, e.g. >10×, significantly increasing in ALT accompanied by elevated , etc.
  • Evidence of liver decompensation, e.g. total bilirubin higher than 2×ULN, albumin lower than 35g/L, is 3 seconds longer than the upper limit of normal, prothrombin activity lower than 60%, or history of decompensated liver cirrhosis, etc.
  • Evidence of hepatocellular carcinoma, or AFP>1×ULN.
  • Significant kidney diseases, including acute nephritis, chronic nephritis, renal insufficiency, nephrotic syndrome, etc. or serum creatinine higher than upper limit of normal.
  • less than 1.5×10\^9/L, or count less than 90×10\^9/L at screening.
  • Serum phosphorus lower than 0.8mmol/L.
  • Antinuclear antibody (ANA) exceeds 1:100.
  • Autoimmune disease, including psoriasis, systemic lupus erythematosus, etc.
  • Subjects with endocrine system disease, including thyroid, Diabetes mellitus, etc.
  • Poorly controlled hypertension (blood pressure ≥140/90 mmHg).
  • Subjects with severe heart disease, especially those with unstable angina or poorly controlled heart disease within 6 months prior to screening.
  • Severe retinopathy or any other severe diseases in the eyes.
  • Subject who had ever received organ transplants or are planning to receive organ transplant.
  • For NAs-treated patients: who have received standard treatment of interferon products within 6 months prior to screening .
  • For treatment naive patients: who have ever received standard treatment of interferon products, or who have ever received NAs within 6 months prior to screening.
  • Subject who are allergic to interferon, tenofovir, or any , or meet any of the described in the drug instructions.
  • Subjects who participated in any other interventional trials within 3 months prior to screening, or with any other conditions which in the opinion of the investigator precluding enrollment from the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    Nucleot(s)ide-treated patients-Experimental Group 1

    Drug: Peginterferon alfa-2b injection

  • Experimental
    Nucleot(s)ide-treated patients-Experimental Group 2

    Drug: Peginterferon alfa-2b injection

  • Active comparator
    Nucleot(s)ide-treated patients-Control Group

    Drug: TDF

  • Other
    Treatment Naive Group

    Drug: Peginterferon alfa-2b injection

Interventions

  • Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.

  • Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.

  • DrugTDF

    Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.

  • Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with HBsAg negative.

    Time frame: 24 weeks post treatment.

Secondary outcomes

  1. Changes of HBsAg level from baseline.

    Time frame: up to 168 weeks.

  2. Proportion of patients with HBsAg seroconversion.

    Time frame: up to 168 weeks.

  3. Proportion of patients with HBeAg negative.

    Time frame: up to 168 weeks

  4. Proportion of patients with HBeAg seroconversion.

    Time frame: up to 168 weeks.

  5. Changes of HBeAg level from baseline.

    Time frame: up to 168 weeks.

  6. Proportion of patients with HBV DNA undetectable.

    Time frame: up to 168 weeks.

  7. Changes of HBV DNA level from baseline.

    Time frame: up to 168 weeks.

  8. Proportion of patients with ALT normalization.

    Time frame: up to 168 weeks.

  9. Proportion of patients with liver fibrosis.

    Time frame: up to 168 weeks.

  10. Proportion of patients with liver cirrhosis.

    Time frame: up to 168 weeks.

07

Study locations

33 sites
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, China
  • Beijing Youan Hospital, Capital Medical University
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • The fifth medical center of PLA General Hospital
    Beijing, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • Xiangya Hospital Central South University
    Changsha, China
  • Public Health Clinical Center of Chengdu
    Chengdu, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Mengchao Hepatobiliary Hosipital of Fujian Medical University
    Fuzhou, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, China
  • The Ninth Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army
    Fuzhou, China
  • Guangzhou Eighth People's Hospital
    Guangzhou, China
  • The Third Affiliated Hospital,SUN YAT-SEN University
    Guangzhou, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
  • Nanjing Drum Tower Hospital/The First Affiliated Hospital of Nanjing University Medical School
    Nanjing, China
  • Huashan Hospital affiliated to Fudan University
    Shanghai, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, China
  • The Sixth People's Hospital of Shenyang
    Shenyang, China
  • Peiking University Shenzhen Hospital
    Shenzhen, China
  • The Third People's Hospital of shenzhen
    Shenzhen, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, China
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
    Tianjin, China
  • Tianjin Third Central Hospital
    Tianjin, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, China
  • Traditional Chinese Medicine hospital of Xinjiang Uygur Autonomous Region
    Urumqi, China
  • Tongji Hospital/Tongji Medical College Huazhong University of Science & Technology
    Wuhan, China
  • Tangdu Hospital
    Xi'an, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • Xiamen Hospital of Traditional Chinese Medicine
    Xiamen, China
  • Yanbian University Hospital/Yanbian Hospital
    Yanbian, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2023, 47 months.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2021
First posted
Apr 15, 2021
StartActual
Dec 4, 2019
Primary completionActual
Nov 30, 2023
CompletionActual
Dec 7, 2023
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04846491
Responsible party
Sponsor
First posted
Apr 15, 2021
Start date
Dec 4, 2019
Primary completion
Nov 30, 2023
Completion
Dec 7, 2023
Last update
Mar 5, 2024

Study contacts

Guiqiang Wang, Ph.D
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion